Nov 30, 2022 / 02:00PM GMT
David Michael Westenberg - Piper Sandler & Co., Research Division - MD & Senior Research Analyst
All right. Thank you, everybody, for coming. Thank you, Illumina, for coming.
Questions and Answers:
David Michael Westenberg - Piper Sandler & Co., Research Division - MD & Senior Research AnalystI'm just going to start off with some of the weakness in the stock yesterday. Some of the things I heard from investors was -- number one, some of the 5% reduction in workforce, if that came before or after -- or you knew about that before or after when you gave long-range guidance or and even guidance for next year. And then number 2 is on the debt rate. So you've talked about some of the refi and some of the dynamics around the refinancing and kick it off that way.
Francis A. deSouza - Illumina, Inc. - CEO & Director
Yes. So look, our expectations on the long-range forecast that we gave or expectations that we gave have not changed, right? So we do expect that NGS and its ability to change how biology
Trustpilot
